Nabi Biopharmaceuticals intends to use proceeds generated through a $32.9 million private placement to help in its purchase of PhosLo and to pay for a Phase III confirmatory trial of StaphVAX. (BioWorld Today)

Nabi Biopharmaceuticals intends to use proceeds generated through a $32.9 million private placement to help in its purchase of PhosLo and to pay for a Phase III confirmatory trial of StaphVAX. (BioWorld Today)

Promising Phase III data plus a respectable bank account prompted CV Therapeutics Inc. to renegotiate with partner Innovex Inc. for a return of all rights associated with the chronic angina candidate Ranexa. (BioWorld Today)

Promising Phase III data plus a respectable bank account prompted CV Therapeutics Inc. to renegotiate with partner Innovex Inc. for a return of all rights associated with the chronic angina candidate Ranexa. (BioWorld Today)